Praxis Precision Medicines, Inc. (PRAX)
Nasdaq: PRAX · Pharmaceutical Preparations · Boston, MA · filing with the SEC since 2016
Who owns Praxis Precision Medicines, Inc.
As filed with the SECHolders of 5% or more
6
Janus Henderson Group PLC holds 12.3% of Common Stock, as its SCHEDULE 13G/A filed Nov 14, 2025 says.
Directors and officers
13
report now, of 19 people on the record since 2020. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 6 named at left.
Holders of 5% or moreshare of the class, as filed
Janus Henderson Group PLC
SCHEDULE 13G/A · filed Nov 14, 2025 · Common Stock · 12.4% in Aug 14, 2025
Fmr LLC
SCHEDULE 13G/A · filed May 6, 2026 · COMMON STOCK · 5.4% in Feb 5, 2026
Perceptive Advisors LLC
SCHEDULE 13G/A · filed Feb 17, 2026 · Common Stock, par value $0.0001 per share · 6.69% in Jul 22, 2025
Baker Bros. Advisors LP
SCHEDULE 13G · filed May 15, 2026 · Common Stock, par value $0.0001 per share
Orbis Investment Management Ltd
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, par value $0.0001 per share · 8.9% in May 15, 2026
Vanguard Capital Management
SCHEDULE 13G · filed Apr 30, 2026 · Common Stock
Venrock Healthcare Capital Partners III, L.P.
SCHEDULE 13G/A · filed May 15, 2025 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 6.1% in Feb 14, 2025
T. Rowe Price Associates, Inc.
SCHEDULE 13G/A · filed Nov 14, 2025 · COMMON STOCK · reported falling below 5%
Soleus Capital Master Fund, L.P.
SCHEDULE 13G/A · filed Aug 5, 2025 · Common Stock, $0.0001 par value per share · reported falling below 5%, from 5% in Mar 19, 2025
Capital Research Global Investors
SCHEDULE 13G/A · filed May 13, 2025 · Common Stock · reported falling below 5%
Cormorant Asset Management, LP
SCHEDULE 13G/A · filed Nov 14, 2025 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 7.72% in Aug 14, 2025
Adage Capital Management, L.P.
SCHEDULE 13G/A · filed Feb 12, 2026 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 5.29% in Nov 3, 2025
Morgan Stanley
SCHEDULE 13G/A · filed Nov 7, 2025 · Common Stock · reported falling below 5%, from 6.2% in Feb 5, 2025
Point72 Biotech Private Investments, LLC
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 6.1% in Feb 17, 2026
The Vanguard Group
SCHEDULE 13G/A · filed Mar 27, 2026 · Common Stock · reported falling below 5%
What PRAX reports owning in othersstakes of 5% or more, and other ties
3 subsidiaries in 2 countries, from the list filed with the 10-K filed Feb 19, 2026.
Insider tradesForm 4
18sales
0purchases
12sales on a scheduled plan
3people selling
$11.1Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window4 of 35 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Gross Phillip | 10% owner | 10 | $33.2M | 0 | 0 | $0 |
| Nemiroff Alex | General Counsel and Secretary | 4 | $4.9M | 0 | 0 | $0 |
| Desimone Jill | director | 12 | $3.6M | 12 | 0 | $0 |
| Mastrocola Lauren | Principal Accounting Officer | 2 | $2.6M | 0 | 0 | $0 |